$Eli Lilly(LLY.US) -4.8% premarket after it cut its profit forecast for FY’25 EPS and CVS Health announced plans to move Lilly’s weight-loss drug, Zepbound, off its list of preferred drugs. Lilly reported 1Q sales of Zepbound roughly in line with expectations. LLY 1Q Revs and EPS beat expectations.
FY’25 Guidance- Adj EPS $20.78-$22.28, saw $22.50 to $24- No change in Rev guidance $58.0B-$61.0B, est $59.7B. 1Q Results- Adj EPS $3.34 vs. $3.26 est- Rev $12.73B vs $12.67B est- Mounjaro rev $3.84B vs $3.77B est- Zepbound rev $2.31B vs $2.29B est-,Verzenio rev $1.16B vs $1.31B est- Jardiance rev. $1.01B vs $735M est- Trulicity rev. $1.1B vs $1.13B est- R&D exp $2.73B vs $2.97B est- Total 1Q rev would have missed by 3%, if not for a Jardiance one-time rev benefit of $370M We are long $Eli Lilly(LLY.US).The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.